Sanofi (NYSE:SNY) had its target price upped by stock analysts at Argus from $48.00 to $50.00 in a note issued to investors on Thursday. The firm presently has a “buy” rating on the stock. Argus’ price target suggests a potential upside of 10.60% from the company’s current price.
A number of other research firms also recently issued reports on SNY. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research note on Wednesday, October 31st. ValuEngine upgraded Sanofi from a “strong sell” rating to a “sell” rating in a research note on Friday, July 20th. Wolfe Research assumed coverage on Sanofi in a research note on Tuesday, October 23rd. They set a “market perform” rating on the stock. Barclays upgraded Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Thursday, November 1st. Finally, BNP Paribas upgraded Sanofi from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 1st. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. Sanofi has a consensus rating of “Hold” and an average price target of $49.50.
Shares of SNY traded down $0.12 during mid-day trading on Thursday, reaching $45.21. The company’s stock had a trading volume of 78,071 shares, compared to its average volume of 1,610,060. Sanofi has a 12-month low of $37.43 and a 12-month high of $46.25. The company has a market cap of $111.91 billion, a P/E ratio of 14.44, a PEG ratio of 2.53 and a beta of 0.70. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22.
In related news, major shareholder Sanofi sold 104,552 shares of the firm’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.00% of the company’s stock.
Institutional investors have recently bought and sold shares of the business. Stratos Wealth Partners LTD. acquired a new stake in Sanofi during the 3rd quarter worth approximately $174,000. Squar Milner Financial Services LLC acquired a new position in Sanofi during the second quarter worth $169,000. Quantum Capital Management acquired a new position in Sanofi during the third quarter worth $202,000. Nisa Investment Advisors LLC acquired a new position in Sanofi during the third quarter worth $205,000. Finally, New England Research & Management Inc. acquired a new position in Sanofi during the third quarter worth $205,000. 7.53% of the stock is owned by institutional investors.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: What is the Book Value of a Share?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.